Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in the last decades, improving the outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking several immune checkpoint pathways, as cytotoxic T lymphocyte...

Descrición completa

Detalles Bibliográficos

Principais autores:	Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, Enrica Teresa Tanda, Lara Vera, Mara Boschetti, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Federico Gatto
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Endocrinology
Assuntos:	immune checkpoint inhibitors cemiplimab diabetic ketoacidosis immune-related adverse events diabetes mellitus anti-PD-1 monoclonal antibody
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1550702/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!